News

ALX Oncology Reveals Key Insights on CD47 Expression in Cancer Treatment

ALX Oncology Reveals Key Insights on CD47 Expression in Cancer Treatment

ALX Oncology Highlights CD47 in HER2+ Gastric Cancer Trials

ALX Oncology Holdings Inc. is set to present significant findings about CD47 expression at an upcoming conference dedicated to cancer immunotherapy. The company, known for its cutting-edge oncology solutions, has gathered data suggesting that CD47 overexpression may serve as a crucial predictive biomarker when using their leading candidate, evorpacept, to treat HER2+ gastric cancer.

Event Details for the Upcoming Presentation

This promising data will be showcased during the poster session at the Society for Immunotherapy of Cancer's (SITC) annual meeting happens shortly. Attendees can look forward to insights based on the Phase 2 ASPEN-06 study, which assessed evorpacept along with other established therapies in treating HER2-positive advanced gastric cancer, a condition notorious for its aggressiveness and limited treatment options.

What to Expect from the Presentation

The presentation, with the compelling title "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial,” will be delivered by Dr. Zev A. Wainberg from the University of California, Los Angeles. Attendees will gain valuable insights on patient outcomes and the significance of CD47 as a biomarker in this specific cancer subtype.

Exploring the ASPEN-06 Trial

ASPEN-06 is an innovative study designed to evaluate the efficacy of evorpacept when combined with HERCEPTIN (trastuzumab), CYRAMZA (ramucirumab), and paclitaxel in treating patients with advanced gastric and gastroesophageal cancers. These patients have often seen their conditions progress despite previous treatments targeting HER2. In this multi-center trial, 127 participants took part, highlighting ALX Oncology's commitment to advancing treatment options in a challenging therapeutic landscape.

Why CD47 Matters

CD47, often referred to as a 'don't eat me' signal, plays a striking role in protecting cancer cells from immune system attack. By targeting CD47, ALX Oncology hopes to enhance treatment efficacy and patient outcomes, making strides towards safer and more effective cancer therapies. The focus on this biomarker aligns with broader trends in cancer treatment that emphasize personalized medicine and targeted therapies.

About ALX Oncology's Pipeline

The company's pipeline is filled with promising candidates designed to tackle various oncological challenges. Evorpacept has shown great potential and is currently undergoing extensive testing across numerous clinical trials. In addition to evorpacept, ALX Oncology is also developing ALX2004, an antibody-drug conjugate targeting EGFR, further diversifying their innovative treatments. The company is committed to turning the tide in cancer therapy, striving to extend life expectancy for patients with difficult-to-treat conditions.

Staying Connected with ALX Oncology

For those interested in the latest updates and developments from ALX Oncology, more information can be found on their official website and social media platforms. Their ongoing commitment to cancer research makes them a key player in the biotech landscape, actively seeking solutions that resonate with patient needs and medical advancements.

Frequently Asked Questions

What is the significance of CD47 expression in cancer treatment?

CD47 has been identified as a potential biomarker that may predict how well patients respond to certain cancer therapies, including evorpacept.

When and where will the presentation take place?

The presentation is scheduled for November 8 during the SITC 40th Annual Meeting, held at the Poster Hall in National Harbor.

How many patients were included in the ASPEN-06 study?

A total of 127 adult patients participated in the Phase 2 portion of the ASPEN-06 trial.

What therapies are being evaluated alongside evorpacept?

Evorpacept is being evaluated in combination with HERCEPTIN, CYRAMZA, and paclitaxel to assess their efficacy in treating advanced gastric cancer.

How can I learn more about ALX Oncology's progress?

You can visit ALX Oncology's website or follow them on social media platforms like LinkedIn for the latest news and updates on their clinical trials and initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Health In Tech's Rocky Q3: Navigating Losses and Opportunities

Updated Category News Views 55

Signs of Optimism Amidst Financial Struggles Health In Tech is wading through the choppy waters of its Q3 2026 financial results—revenue came in at $6.6 million, down from $8.5 million the previous year. Seems like their investments are all geared up, but the sails aren’t quite catching wind yet. That said, their contracted revenue strutted to $32.7 million for the...

Continue Reading
Funding Fuels LCH2's Vision for Clean Energy Campus

Updated Category News Views 88

Money Talks: LCH2 Scores Big Again Just when you think it's all talk, they pony up another million bucks. The Lewis County Hydrogen Alliance, otherwise known as LCH2, didn't stop with a decent $400k earmark. Nope, they just went ahead and snagged an additional $1 million from TransAlta Centralia. This ain't chump change—it brings their total grant pile to a solid $1.4...

Continue Reading
Veterans Guardian Earns 2026 Gold HIRE Vets Medallion

Updated Category News Views 86

Veterans Guardian Celebrates Another Milestone Alright, folks, let me hit you with a piece of news that didn't just skim across the ticker like another stock price—this one's truly for the soul. Veterans Guardian VA Claim Consulting out of Pinehurst, North Carolina, snagged the 2026 Gold HIRE Vets Medallion Award from the U.S. Department of Labor. It's a nod that goes...

Continue Reading
Major Richard Star Act: A Long Overdue Milestone

Updated Category News Views 142

Hard-Won Gains for Our Combat Veterans Washington took a significant stride today—one that feels long overdue as the House of Representatives passed the Major Richard Star Act. This isn't just some routine legislative shuffle; this is the gritty, life-impacting work that cuts to the core of what it means to support those who defended our country. We're talking about...

Continue Reading
Global Case Studies in Poverty Reduction Spotlighted

Updated Category News Views 41

A Fresh Spotlight on Poverty Reduction Efforts Amid the clamor of social and economic challenges, 126 stellar case studies of poverty reduction just took center stage at a seminar in Beijing. These admired initiatives emerged from the seventh global solicitation, chosen from a pile of 890 entries submitted by do-gooders and organizations spanning 31 countries. If you've...

Continue Reading
Olympus Gains U.S. Reimbursement for GI Procedure

Updated Category News Views 64

Olympus Secures Reimbursement for Vital GI Procedure When it comes to navigating the health sector, you learn to spot the plays that set the stage for long-term change. Olympus Corporation just announced something worth your attention if you're eyeing the med-tech world. The Centers for Medicare & Medicaid Services (CMS) have greenlit reimbursement rates for the...

Continue Reading
DeFi Tech Q3 2026: Navigating Cash Strong Waters

Updated Category News Views 18

DeFi Technologies: Holding Steady as Markets Sway DeFi Technologies Inc. has just thrown its quarterly earnings into the ring. With $18.3 million in revenue and a net income of $22.3 million, this digital asset dynamo is showing signs of resilience, even as the financial seas continue their wild dance. For those of us watching the NASDAQ:DEFT like hawks, these figures...

Continue Reading
Navigating Idaho's Massage Therapy School Pathways

Updated Category News Views 98

Cracking the Idaho Massage School Code Idaho folks diving into massage therapy education need a playbook—timing, training, and all the bumps along the way. This journey's not just book reading and back rubs; it’s a structured affair with rigid hours and some bureaucratic hurdling. Thank goodness for Kylee Evans, who’s spilling the beans on what goes down in Idaho...

Continue Reading
MJ Cultivate: A New Stage for Cannabis Pioneers

Updated Category News Views 35

Spotlight on Cannabis Innovators Look, anyone with skin in the game knows the cannabis industry is more than just shimmering stores and glossy products. It's got deep roots, and those roots grow from the hands of folks tirelessly working the soil, engineering extracts, and perfecting every last breath of a bud. That's who Jage Media's latest brainchild, MJ Cultivate,...

Continue Reading
Coastal Financial Faces $470M Wipeout: Investor Alert

Updated Category News Views 69

Revelations Hit Coastal Financial Hard Alright, pull up a chair and let’s chew over what just happened with Coastal Financial Corporation (NASDAQ: CCB). This is the sort of deal that makes seasoned investors shake their heads in disbelief. Between October 28, 2024, and July 29, 2026, anyone buying into Coastal was buying into a mess they didn’t sign up for. We're...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking America's Hidden Resources: A Path to Prosperity

Updated Category News Views 271

Unlocking America’s Hidden Resources: A Path to Prosperity In today's economic landscape, a pressing topic arises as some resources remain largely overlooked. A recent presentation by a former CIA advisor has brought to light the potential of utilizing neglected federal resources to bolster the economy. This shift could play a crucial role in America's economic recovery...

Continue Reading
Hong Kong's Talent Takes Center Stage with Now United

Updated Category News Views 187

Celebrating Homegrown Talent with a Global Reach The Hong Kong Jockey Club, in collaboration with the renowned XIX Entertainment, announced a thrilling new chapter in the realm of global music by introducing Ariel Tsang as the first member of the pop group Now United from Hong Kong. This exciting development occurred during a media event at Tai Kwun, where Ariel made her...

Continue Reading
Silfab Solar and Pivot Energy Unite for Sustainable Growth

Updated Category News Views 438

Silfab Solar Partners with Pivot Energy for Major Supply Deal Silfab Solar Inc., recognized for its leadership in the solar industry, has teamed up with Pivot Energy, a respected renewable energy provider. This collaboration marks a significant milestone as they announce a 350 megawatt (MW) supply agreement aimed at bolstering America's solar capacity and supporting...

Continue Reading
Actuate Reveals Cleantech's Untapped Potential

Updated Category News Views 23

Pioneering Predictive Building Intelligence In the world of building management, size often dictates access to technology. Yet here comes Actuate, flipping the script and delivering cutting-edge, predictive building intelligence to operators who manage the unsung portfolios of small and mid-sized commercial properties. We're talking about the vast 80% of commercial...

Continue Reading
Design Therapeutics Announces Participation in Key Conferences

Updated Category News Views 173

Investor Conference Participation by Design Therapeutics Design Therapeutics, Inc. (NASDAQ: DSGN), a pioneering biotechnology company based in Carlsbad, California, is preparing to take part in significant investor conferences. These events provide a platform for discussing their groundbreaking work in developing treatments aimed at serious degenerative genetic diseases....

Continue Reading